首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2029988

全球新生兒篩檢市場：按檢測類型、產品類型、技術和地區分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Newborn Screening Market: By Test Type, Product, Technology, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

出版日期: 2026年04月28日 | 出版商:

Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

新生兒篩檢市場正處於強勁成長期，反映出全球對疾病早期檢測和預防醫學日益成長的關注。 2025年，該市場規模約為9.8209億美元，預計到2035年將達到約20.3905億美元。此成長意味著2026年至2035年預測期間的複合年成長率（CAGR）為7.58%，顯示全球對新生兒診斷基礎設施的需求持續旺盛，且相關投資也將持續成長。

推動這一成長的主要動力是對先天性和遺傳性疾病早期發現和管理的日益關注。在已開發國家和發展中國家的醫療保健系統中，新生兒篩檢正日益成為一項重要的公共衛生措施。早期識別代謝、內分泌和遺傳異常有助於及時治療，從而顯著降低長期殘疾和死亡率。這種預防性方法使新生兒篩檢成為現代兒童醫療保健策略的重要組成部分。

顯著的市場趨勢

全球新生兒篩檢市場主要由少數幾家領先的一級企業主導，其中珀金埃爾默（PerkinElmer）和沃特世公司（Waters Corporation）憑藉其豐富的經驗、龐大的檢測量和一體化的診斷解決方案，佔據了尤為穩固的地位。珀金埃爾默憑藉其新生兒篩檢業務的龐大規模，成為該領域最具影響力的公司之一。據估計，該公司每年協助篩檢約3,900萬名新生兒，體現了其在全球新生兒診斷領域的強大影響力。

同樣，沃特世公司憑藉其在全球新生兒篩檢檢查室部署分析儀器的豐富經驗，保持強大的競爭優勢。該公司已在臨床和研究領域部署了超過10,000台儀器，在診斷工作流程中擁有根深蒂固的地位。憑藉這一成功經驗，沃特世公司能夠獲得長期服務契約，從而獲得可預測且持續的收入來源。

在二級市場領域，Natas Medical 在新生兒聽力篩檢這一專業領域中扮演著特別重要的角色。該公司透過生產和銷售超過 5 萬台專用聽力篩檢設備，在全球建立了強大的影響力。憑藉對這一領域的專注，Natas Medical 在社區聽力篩檢佔據了主導地位，而早期療育對於兒童的長期發展至關重要。

主要成長要素

全球新生兒篩檢的需求源自於龐大的新生兒數量，估計每年約有1.34億新生兒出生。如此龐大的新生兒群體構成了已開發國家和發展中國家新生兒醫療保健服務的消費群。由於新生兒需要接受各種生理和遺傳疾病的評估，而這些疾病在出生時並不明顯，因此每次分娩都需要立即進行產後醫療護理。

新機會的趨勢

在全球新生兒篩檢市場中，報銷政策對臨床實驗室診斷的普及應用起著至關重要的作用。醫療系統和診斷服務提供者在評估大規模篩檢計畫的財務可行性時，通常會依賴結構化的報銷框架。當報銷機製完善且有利時，就能確保檢查室能收回與檢測、試劑和營運基礎設施相關的成本，從而促進新生兒篩檢的更廣泛實施。因此，政策設計直接影響各地區篩檢計畫的實施範圍與效率。

最佳化障礙

在一些發展中地區，先進診斷設施的匱乏限制了新生兒篩檢市場的成長。許多中低收入國家仍缺乏能夠大規模進行全面新生兒篩檢的設備齊全的檢查室。因此，即使篩檢項目已被強製或推薦，基礎設施的不足也限制了其在所有地區的持續實施。這種診斷能力的差距導致早期疾病檢測服務取得不平衡，尤其是在都市區和農村或偏遠地區之間。

產業價值鏈分析
產業展望
- 開發中國家出生率上升
- 提高對疾病早期檢測的認知
- 政府強制篩檢計劃
- 技術進步（串聯式質譜法、基因檢測）
- 擴大篩檢項目
PESTLE分析
波特五力分析
市場動態和趨勢
- 成長要素
  - 對疾病早期檢測和預防需求的不斷成長正在推動市場成長。
- 抑制因子
- 機會
- 主要趨勢
市場成長及前景
- 2020-2035年市場收入估算與預測
- 價格趨勢分析

第4章：競爭對手儀錶板

市場集中度
企業市場占有率分析，2025 年
競爭對手分析與基準測試
Start-Ups生態系分析
併購和資金籌措趨勢

第5章：全球新生兒篩檢市場分析

關鍵見解
市場規模及預測，2020-2035年
- 依產品
  - 試劑
  - 裝置
- 透過技術
  - 脈搏血氧計
  - 串聯式質譜質譜法
  - 基於酵素的檢測
  - 電泳
  - DNA檢測
  - 其他
- 按測試類型
  - CCHD
  - 乾血斑測試
  - 聽力篩檢
- 按地區
  - 北美洲
    - 美國
    - 加拿大
    - 墨西哥
  - 歐洲
    - 西歐
      - 英國
      - 德國
      - 法國
      - 義大利
      - 西班牙
      - 其他西歐國家
    - 東歐
      - 波蘭
      - 俄羅斯
      - 其他東歐國家
  - 亞太地區
    - 中國
    - 印度
    - 日本
    - 韓國
    - 澳洲和紐西蘭
    - ASEAN
      - 印尼
      - 馬來西亞
      - 泰國
      - 新加坡
      - 其他東協國家
    - 亞太其他地區
  - 中東和非洲
    - UAE
    - 沙烏地阿拉伯
    - 南非
    - 其他中東和非洲
  - 南美洲
    - 阿根廷
    - 巴西
    - 南美洲其他地區

第6章：北美新生兒篩檢市場分析

第7章：歐洲新生兒篩檢市場分析

第8章：亞太地區新生兒篩檢市場分析

第9章：中東和非洲新生兒篩檢市場分析

第10章：南美洲新生兒篩檢市場分析

第11章：公司簡介

Abionic SA
PerkinElmer Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Waters Corporation
Bio-Rad Laboratories Inc.
Trivitron Healthcare
Masimo Corporation
Natus Medical Incorporated
Medtronic plc
Baebies, Inc.
Cordlife Group Limited
Demant A/S
GE Healthcare
Hill-Rom Holdings, Inc.
Metascreen
Natera, Inc.
OZ Systems
Revvity
Zentech SA
Danaher Corporation
Other Prominent Players

第12章附錄

簡介目錄

Product Code: AA04261772

The newborn screening market is on a strong growth trajectory, reflecting increasing global emphasis on early disease detection and preventive healthcare. In 2025, the market is valued at approximately USD 982.09 million, and it is projected to reach around USD 2,039.05 million by 2035. This expansion corresponds to a compound annual growth rate (CAGR) of 7.58% during the forecast period from 2026 to 2035, indicating sustained demand and continued investment in neonatal diagnostic infrastructure worldwide.

A major factor driving this growth is the rising focus on early detection and management of congenital and genetic disorders. Healthcare systems across both developed and developing regions are increasingly prioritizing newborn screening as a critical public health intervention. Early identification of metabolic, endocrine, and genetic abnormalities allows for timely treatment, significantly reducing long-term disability and mortality rates. This preventive approach has made newborn screening an essential component of modern pediatric healthcare strategies.

Noteworthy Market Developments

The global newborn screening market is largely shaped by a small number of dominant Tier 1 players, with companies such as PerkinElmer and Waters Corporation holding particularly strong positions due to their extensive installed bases, high testing volumes, and integrated diagnostic solutions. PerkinElmer stands out as one of the most influential participants in this space, largely due to the scale of its newborn screening operations. The company is estimated to support the screening of approximately 39 million newborns annually, reflecting its strong global footprint in neonatal diagnostics.

Similarly, Waters Corporation maintains a strong competitive position through its extensive installed base of analytical instruments used in newborn screening laboratories worldwide. With more than 10,000 instruments deployed across clinical and research settings, the company benefits from a deeply embedded presence in diagnostic workflows. This installed base enables Waters Corporation to secure long-term service contracts that provide highly predictable and recurring revenue streams.

In the Tier 2 segment, Natus Medical plays a significant role, particularly in the specialized area of newborn hearing screening. The company has established a strong global presence through the manufacture and distribution of over 50,000 dedicated audiology screening devices. By focusing on this specialized segment, Natus Medical has secured a dominant position in localized audiology screening, where early intervention is essential for long-term developmental outcomes.

Core Growth Drivers

Global demand for newborn screening begins with the enormous scale of worldwide births, which is estimated at approximately 134 million annually. This vast birth cohort forms the foundational consumer base for neonatal healthcare services across both developed and developing regions. Each birth represents an immediate requirement for postnatal medical attention, as newborns must be assessed for a range of physiological and genetic conditions that are not externally visible at birth.

Emerging Opportunity Trends

Reimbursement policies play a crucial role in influencing the adoption of laboratory diagnostics within the global newborn screening market. Healthcare systems and diagnostic providers often rely on structured reimbursement frameworks to determine the financial viability of large-scale screening programs. When reimbursement mechanisms are well-established and favorable, they encourage broader implementation of newborn screening by ensuring that laboratories can recover costs associated with testing, reagents, and operational infrastructure. As a result, policy design directly affects how widely and efficiently screening programs are adopted across different regions.

Barriers to Optimization

The growth of the newborn screening market is being constrained in several developing regions due to the limited availability of advanced diagnostic facilities. Many low- and middle-income countries still lack adequately equipped laboratories capable of performing comprehensive neonatal screening at scale. As a result, even when screening programs are mandated or recommended, the absence of sufficient infrastructure restricts their consistent implementation across all regions. This gap in diagnostic capacity leads to uneven access to early disease detection services, particularly between urban centers and rural or remote areas.

Detailed Market Segmentation

By product, the instruments segment accounted for the largest share of the newborn screening market, representing approximately 75.86% of total revenue. This dominant position reflects the inherently capital-intensive nature of neonatal diagnostic infrastructure, where large upfront investments are required to establish fully equipped laboratory facilities. Hospitals and diagnostic centers must allocate significant capital expenditure to procure advanced analytical systems, which form the backbone of modern newborn screening programs.

By technology, the tandem mass spectrometry segment held the largest share of the newborn screening market, accounting for approximately 27.23%. This leading position reflects its strong clinical utility and widespread adoption in modern neonatal diagnostic workflows. Tandem mass spectrometry has become a cornerstone technology in newborn screening due to its high analytical precision, efficiency, and ability to process a large number of samples in a short period of time, making it highly suitable for population-scale screening programs.

By test type, the dry blood spot (DBS) test segment dominated the newborn screening market in 2025, accounting for the highest market share of approximately 72%. This strong leadership position is primarily attributed to its operational simplicity, cost efficiency, and exceptional suitability for large-scale public health screening programs. The method involves collecting a small blood sample from a newborn's heel onto specialized filter paper, which is then dried and transported to laboratories for analysis. This straightforward collection process makes it highly practical for use in both advanced healthcare systems and resource-limited settings.

Segment Breakdown

By Product

Instruments
Reagents

By Technology

Tandem Mass Spectrometry
Pulse Oximetry
Enzyme-Based Assay
DNA Assay
Electrophoresis
Others

By Test Type

Dry Blood Spot Test
CCHD
Hearing Screen

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

Asia Pacific held the leading position in the global newborn screening market in 2025, accounting for the highest regional market share of approximately 31%. This dominance is strongly linked to the region's large and diverse population base, which consistently generates some of the highest annual birth volumes in the world. China remains the single largest contributor to regional birth numbers, with approximately 9 million births recorded annually. This substantial birth cohort creates significant pressure on healthcare systems to ensure early detection of metabolic, genetic, and congenital disorders through standardized screening programs.
Across the Asia Pacific region, millions of annual births collectively require extensive and well-organized pediatric healthcare networks. As a result, governments and private healthcare providers have been investing heavily in the expansion and modernization of neonatal screening capabilities. Infrastructure development is advancing rapidly, with increasing adoption of automated laboratory systems, high-throughput diagnostic platforms, and digital health integration.
India has emerged as a key growth center within this regional landscape, operating more than 150 dedicated newborn screening centers across various states. These specialized facilities are designed to manage rising sample volumes efficiently while ensuring standardized testing protocols. The increasing number of births, combined with expanding awareness of early disease detection, has led to continuously growing daily testing loads.

Leading Market Participants

Abionic SA
Agilent Technologies, Inc.
Baebies, Inc.
Bio-Rad Laboratories, Inc.
Cordlife Group Limited
Demant A/S
GE Healthcare
Hill-Rom Holdings, Inc.
Masimo Corporation
Medtronic plc
Metascreen
Natera, Inc.
Natus Medical Incorporated
OZ Systems
PerkinElmer, Inc.
Revvity
Thermo Fisher Scientific Inc.
Trivitron Healthcare
Waters Corporation
Zentech S.A.
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Newborn Screening Market

Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
- 2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
- 2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global Newborn Screening Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Raw Material Suppliers (Reagents, Consumables)
- 3.1.2. Equipment Manufacturers (Screening Devices)
- 3.1.3. Diagnostic Laboratories & Hospitals
- 3.1.4. Government & Public Health Agencies
- 3.1.5. Distribution Channels
3.2. Industry Outlook
- 3.2.1. Rising Birth Rates in Developing Countries
- 3.2.2. Increasing Awareness of Early Disease Detection
- 3.2.3. Government-Mandated Screening Programs
- 3.2.4. Technological Advancements (Tandem Mass Spectrometry, Genetic Testing)
- 3.2.5. Expansion of Screening Panels
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Dynamics and Trends
- 3.5.1. Growth Drivers
  - 3.5.1.1. Increasing Need for Early Disease Detection & Prevention is drive the market growth
- 3.5.2. Restraints
- 3.5.3. Opportunity
- 3.5.4. Key Trend
3.6. Market Growth and Outlook
- 3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2035
- 3.6.2. Price Trend Analysis

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking
4.4. Startup Ecosystem Analysis
4.5. M&A and Funding Landscape

Chapter 5. Global Newborn Screening Market Analysis

5.1. Key Insights
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Product
  - 5.2.1.1. Reagents
  - 5.2.1.2. Instruments
- 5.2.2. By Technology
  - 5.2.2.1. Pulse Oximetry
  - 5.2.2.2. Tandem Mass Spectrometry
  - 5.2.2.3. Enzyme Based Assay
  - 5.2.2.4. Electrophoresis
  - 5.2.2.5. DNA Assay
  - 5.2.2.6. Others
- 5.2.3. By Test Type
  - 5.2.3.1. CCHD
  - 5.2.3.2. Dry Blood Spot Test
  - 5.2.3.3. Hearing Screen
- 5.2.4. By Region
  - 5.2.4.1. North America
    - 5.2.4.1.1. The U.S.
    - 5.2.4.1.2. Canada
    - 5.2.4.1.3. Mexico
  - 5.2.4.2. Europe
    - 5.2.4.2.1. Western Europe
      - 5.2.4.2.1.1. The UK
      - 5.2.4.2.1.2. Germany
      - 5.2.4.2.1.3. France
      - 5.2.4.2.1.4. Italy
      - 5.2.4.2.1.5. Spain
      - 5.2.4.2.1.6. Rest of Western Europe
    - 5.2.4.2.2. Eastern Europe
      - 5.2.4.2.2.1. Poland
      - 5.2.4.2.2.2. Russia
      - 5.2.4.2.2.3. Rest of Eastern Europe
  - 5.2.4.3. Asia Pacific
    - 5.2.4.3.1. China
    - 5.2.4.3.2. India
    - 5.2.4.3.3. Japan
    - 5.2.4.3.4. South Korea
    - 5.2.4.3.5. Australia & New Zealand
    - 5.2.4.3.6. ASEAN
      - 5.2.4.3.6.1. Indonesia
      - 5.2.4.3.6.2. Malaysia
      - 5.2.4.3.6.3. Thailand
      - 5.2.4.3.6.4. Singapore
      - 5.2.4.3.6.5. Rest of ASEAN
    - 5.2.4.3.7. Rest of Asia Pacific
  - 5.2.4.4. Middle East & Africa
    - 5.2.4.4.1. UAE
    - 5.2.4.4.2. Saudi Arabia
    - 5.2.4.4.3. South Africa
    - 5.2.4.4.4. Rest of MEA
  - 5.2.4.5. South America
    - 5.2.4.5.1. Argentina
    - 5.2.4.5.2. Brazil
    - 5.2.4.5.3. Rest of South America

Chapter 6. North America Newborn Screening Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Test Type
- 6.2.4. By Country

Chapter 7. Europe Newborn Screening Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Test Type
- 7.2.4. By Country

Chapter 8. Asia Pacific Newborn Screening Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Test Type
- 8.2.4. By Country

Chapter 9. Middle East & Africa Ground Newborn Screening Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Test Type
- 9.2.4. By Country

Chapter 10. South America Newborn Screening Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Test Type
- 10.2.4. By Country